The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2024 | Stool-based testing in colorectal cancer screening
Theodore R. Levin, MD, Kaiser Permanente, Oakland, CA emphasizes the key point that when it comes to colorectal cancer screening, stool-based testing offers a significant advantage in terms of adherence rates compared to relying solely on colonoscopy. He highlights that regular stool-based testing can be as effective as colonoscopy in various settings. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
